Screening, Diagnosis, and Treatment of Hepatitis C Virus
2014 CORE Curriculum Activities

Program Overview

Chronic hepatitis C virus (HCV) infection represents a substantial health problem in the US, and the rate of mortality associated with the disease is predicted to increase exponentially over the next decade. To prevent this outcome, individuals at high risk for infection must be screened so that those infected can be promptly diagnosed and treated to improve patient outcomes. With appropriate treatment, HCV infection is curable and liver-related morbidity and mortality can be significantly reduced. Although optimal treatment regimens have yet to be determined, the expansion of available direct-acting antiviral agents (DAAs) has already enabled shorter, better-tolerated treatment courses for the majority of patients, and has raised the possibility of even more effective interferon-free regimens in the future.

2014 Continuous Outreach for Retention of Education (CORE) HCV Curriculum

The 2014 CORE HCV Curriculum has been designed to provide healthcare providers involved in the diagnosis and management of patients with HCV a serial learning intervention delivered over the course of 12 weeks. The CORE Curriculum includes a series of live educational activities and short online enduring materials reinforcing the content presented in the live meetings. CORE Curriculum modules are available to all Practitioner’s Edge visitors. We encourage you to check back soon for additional modules in this curriculum that have been designed to enhance healthcare provider knowledge, competence, and performance in the diagnosis and management of patients with HCV.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

Disclosure of Conflicts of Interest

All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (eg, stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. For the purposes of CME accreditation National Jewish Health considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

All CME Educational Activities sponsored by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation by our faculty CME committee. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Patima Tanapat, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Miranda Ku, MD, has no financial interests/relationships or affiliations in relation to this activity.
Ariana Greenwood, MD, has no financial interests/relationships or affiliations in relation to this activity.

National Jewish Health

For questions about the accreditation of these activities, please contact National Jewish Health at 800-844-2305 or visit

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.

Disclosure of Unlabeled Use

These educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Jewish Health and Integrity Continuing Education, Inc., do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of National Jewish Health, Integrity Continuing Education, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided in these activities is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Module 1

Module 2

Module 3


Case Study Exercise and Review


Release date: August 26, 2014
Expiration date: August 26, 2015
Estimated time to complete activity: 0.25 hour
Release date: October 3, 2014
Expiration date: October 3, 2015
Estimated time to complete activity: 0.50 hour
Release date: December 2, 2014
Expiration date: December 2, 2015
Estimated time to complete activity: 1.25 hours





NJH new   integrity 
Co-sponsored by National Jewish Health and Integrity Continuing Education, Inc.
This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech.